- WuXi Biologics will provide an exclusive license to GSK for one
preclinical bi-specific T cell engaging (TCE) antibody and the
option of three additional bi-/multi-specific TCE antibodies
developed using WuXi Biologics' proprietary technology
platforms
- WuXi Biologics will receive an upfront payment of $40 million and tiered royalties on net
sales
SHANGHAI, Jan. 4, 2023
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading
global Contract Research, Development, and Manufacturing
Organization (CRDMO), today announced a license agreement with GSK
plc (LSE/NYSE: GSK) under which GSK will have exclusive licenses
for up to four bi- & multi-specific TCE antibodies developed
using WuXi Biologics' proprietary
technology platforms.
Under the terms of the agreement, GSK will be granted an
exclusive global license for the research, development,
manufacturing, and commercialization of a pre-clinical bispecific
antibody that crosslinks tumor cells and T cells by targeting a
tumor-associated antigen (TAA) on tumor cells and CD3 expression on
T cells and up to three additional pre-clinical TCE antibodies
currently at an earlier discovery stage. WuXi Biologics will
receive a $40 million upfront payment
and up to $1.46 billion in additional
payments for research, development, regulatory and commercial
milestones across the four TCE antibodies. WuXi Biologics is also
eligible to receive tiered royalties on net sales.
Dr. Chris Chen, CEO of WuXi
Biologics, commented, "This license agreement with GSK represents
an important validation of our potential best-in-class CD3 platform
and WuXiBody® platform, the 'R' in our CRDMO business model. This
also demonstrates our efforts in offering global open-access
technology platforms with premier quality and excellent execution.
We are looking forward to enabling GSK to bring these potentially
life-saving therapeutics to more patients worldwide."
John Lepore, Senior Vice
President, Head of Research GSK, said, "This agreement with WuXi
Biologics builds on our oncology portfolio of tumor cell targeting
agents by providing GSK with access to potential best-in-class
T-cell engaging antibodies that have been optimized for effective
tumor killing with a desirable safety profile, offering the
potential to address significant unmet medical need in patients
with multiple tumor types."
About WuXiBody®
WuXiBody® is a leading proprietary bispecific antibody platform
developed by WuXi Biologics. It can effectively break through the
discovery and CMC barriers for the development of many bispecific
antibodies with high expression yield, high stability, good
solubility, and easy purification to homogeneity, expedite the
process by 6-18 months and significantly reduce manufacturing
costs, a limitation still faced by many other current bispecific
platforms. WuXiBody® platform enables almost any mAb sequence pairs
to be assembled into bispecific constructs, which are expected to
have low immunogenicity risk and longer in vivo half-life.
WuXiBody® platform also has a unique structural flexibility, which
makes it convenient to build various formats with different
combinations of valencies (1+1, 1+2, 2+2) to meet the requirements
of different target biology.
In addition to WuXiBody®, WuXi Biologics also developed a suite
of proprietary bispecific and multispecific antibody platforms
including VHH antibody-based SDArBodyTM, stabilized
scFv-based SkyBodyTM, and have access to OmniFlic® rats
to generate common light chain-based bispecific antibody through
collaboration with Ligand. These platforms together with the
flagship platform, WuXiBody®, enable WuXi Biologics to make various
bispecific and multi-specific antibodies to meet various biology
needs of the company's clients, including to support development of
assets in the GSK license agreement.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global
Contract Research, Development and Manufacturing Organization
(CRDMO) offering end-to-end solutions that enable partners to
discover, develop and manufacture biologics – from concept to
commercialization – for the benefit of patients worldwide.
With over 10,000 skilled employees in China, the United
States, Ireland,
Germany and Singapore, WuXi Biologics leverages its
technologies and expertise to provide customers with efficient and
cost-effective biologics discovery, development and manufacturing
solutions.
WuXi Biologics views Environmental, Social, and Governance (ESG)
responsibilities as an integral component of our ethos and business
strategy, and we aim to become an ESG leader in the biologics CRDMO
sector. Our facilities use next-generation biomanufacturing
technologies and clean-energy sources. We have also established an
ESG committee led by our CEO to steer the comprehensive ESG
strategy and its implementation, enhancing our commitment to
sustainability.
For more information about WuXi Biologics, please visit:
www.wuxibiologics.com.
Contacts
Media
PR@wuxibiologics.com
Business
info@wuxibiologics.com
View original
content:https://www.prnewswire.com/news-releases/wuxi-biologics-and-gsk-enter-into-license-agreement-on-multiple-novel-bi---multi-specific-t-cell-engagers-301713506.html
SOURCE WuXi Biologics